Alaunos Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Alaunos Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). High-risk early-stage biotech with dual targeted therapies in large markets, but substantial development and funding risks ahead. Early-stage clinical pipeline with promising preclinical obesity data and TCR-T cell platform, but minimal revenue and high cash burn typical of pre-revenue biotech. Recent ALN1003 data shows therapeutic potential but company remains.
What is Alaunos Therapeutics, Inc.'s industry? Alaunos Therapeutics, Inc. (alaunos.com) operates in Biopharmaceutical / Cell Therapy. AskCyborg classifies Alaunos Therapeutics, Inc. under Biopharmaceutical / Cell Therapy in its company registry.
Alaunos Therapeutics is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The company is developing dual therapeutic programs targeting high-growth market opportun...
Cyborg Score thesis
High-risk early-stage biotech with dual targeted therapies in large markets, but substantial development and funding risks...
Read the full analyst-debate transcript →Get the Latest Alaunos Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAlaunos Therapeutics, Inc. Overview
Pro stress-test →Alaunos Therapeutics is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The company is developing dual therapeutic programs targeting high-growth market opportunities in metabolic diseases and solid tumors through novel small molecule and cell therapy approaches.
Strategic Profile
Pro stress-test →The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. Alaunos engages in the development of adoptive TCR engineered T-cell therapies designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs.
Competitive Landscape
Pro stress-test →Alaunos competes in two distinct markets: the obesity/metabolic space against well-capitalized pharma with GLP-1 agonists (Novo Nordisk, Eli Lilly), and in oncology TCR-T cell therapy against established CAR-T developers and emerging TCR specialists. The company's oral obesity approach differentiates from injectables, while its TCR platform targets the expanding T-cell therapy space.
Industry Context
Alaunos Therapeutics, Inc. operates in Biopharmaceutical / Cell Therapy.
Key facts
Founded: 2003 · Headquarters: Houston, Texas · Market cap: $6.6M